Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcarePBH -2.24%69 Peter Lynch Fair Value is $53.62 as of Aug. 20, 2026, which is 3730% above its 10-year median of 1.40. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 257 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 61.87% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Prestige Consumer Healthcare's PEG is 1. Prestige Consumer Healthcare's 5-Year TTM EBITDA Growth Rate is 14.61.
Prestige Consumer Healthcare's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $3.67. Therefore, the Peter Lynch Fair Value for today is $53.62.
The historical rank and industry rank for Prestige Consumer Healthcare's Peter Lynch Fair Value or its related term are showing as below:
PBH'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.55 Med: 1.4 Max: 2.76
Current: 0.94
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Prestige Consumer Healthcare was 2.76. The lowest was 0.55. And the median was 1.40.
PBH's Price-to-Peter-Lynch-Fair-Value is ranked better than 61.87% of 257
companies
in the Drug Manufacturers industry
Industry Median: 1.24
vs PBH: 0.94
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Prestige Consumer Healthcare (NYSE:PBH) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 14.61 instead of 15 in this case.
Prestige Consumer Healthcare's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
50.52
/
53.62
=
0.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare Peter Lynch Fair Value Related Terms
Prestige Consumer Healthcare Peter Lynch Fair Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare Peter Lynch Fair Value Chart
PBH vs BCRX, AMLX, SUPN: Peter Lynch Fair Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's Price-to-Peter-Lynch-Fair-Value falls into.
Prestige Consumer Healthcare's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.67.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of $53.62 mean?
Prestige Consumer Healthcare (PBH) has a Peter Lynch Fair Value of $53.62 as of Aug. 20, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Prestige Consumer Healthcare and its competitors. This is 3730% above median its historical median of 1.40. Over the past decade, Prestige Consumer Healthcare's Peter Lynch Fair Value has ranged from 0.55 to 2.76. According to the industry distribution chart, Prestige Consumer Healthcare ranks #98 out of 257 companies in the Drug Manufacturers industry, placing it in the top 38.1%.
Is Prestige Consumer Healthcare's Peter Lynch Fair Value too high?
Prestige Consumer Healthcare's current Peter Lynch Fair Value of $53.62 is 3730% above median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 2.76. The Drug Manufacturers industry median Peter Lynch Fair Value is 1.24. Prestige Consumer Healthcare's value of $53.62 is 4224.2% above this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #98 out of 257 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Peter Lynch Fair Value compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #98 out of 257 companies for Peter Lynch Fair Value. This puts Prestige Consumer Healthcare in the upper half of its industry. The industry median Peter Lynch Fair Value is 1.24. Prestige Consumer Healthcare's value of $53.62 is 4224.2% above this benchmark. Historically, Prestige Consumer Healthcare's own Peter Lynch Fair Value has ranged from 0.55 to 2.76 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 1.24, Prestige Consumer Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.24, based on 257 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current Peter Lynch Fair Value of $53.62 is 4224.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current Peter Lynch Fair Value is $53.62, which is 3730% above median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current Peter Lynch Fair Value is $53.62, which is 3730% above median its 10-year median of 1.40 and 4224.2% above the Drug Manufacturers industry median of 1.24. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current Peter Lynch Fair Value is $53.62 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
Peter Lynch Fair Value: $53.62 (3730% above median its 10-year median of 1.40)
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 4224.2% above the Drug Manufacturers median (#98 of 257)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
